pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,273 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT806Endpoints605BioPharma Dive231onclive165Fierce Biotech74BioSpace71raps32fda press20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • FDA OKs first new sunscreen ingredient in more than 25 years
    Federal health regulators on Tuesday signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years.
    STAT · 1mo ago↗ source
  • Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
    BioPharma Dive · 1mo ago↗ source
  • Stealthy startup Treeline plans a reverse merger
    Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
    BioPharma Dive · 1mo ago↗ source
← prev
page 24 of 51
next →
20
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Trump administration warns more than 500 hospitals to provide more price information or face fines
    The Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information.
    STAT · 1mo ago↗ source
  • Gilead and Merck’s latest trial success and flop
    AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: NIAID appoints new acting director after weekslong questions over leadership
    The NIH has appointed researcher John Powers III to lead its infectious disease institute on an acting basis, after weeks of being in leadership limbo.
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
    GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
    STAT · 1mo ago↗ source
  • Dexcom RCT suggests CGM benefits for broad diabetes population
    In this edition of STAT Health Tech: Dexcom's CGM trial, udpates from Apple's annual developers' conference, and wearables.
    STAT · 1mo ago↗ source
  • GSK boosts cancer pipeline with $11B Nuvalent buyout
    The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: NIH staffers published a letter of dissent a year ago. They feel it’s been ignored
    In a report published on the first anniversary of the Bethesda Declaration, 71 staffers write that they feel NIH leadership “largely ignored" their concerns.
    STAT · 1mo ago↗ source
  • STAT+: What’s changed since the last major Ebola outbreak
    A suppressed federal alcohol report, an "inevitable development" for wearables data, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough
    “Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.
    STAT · 1mo ago↗ source
  • STAT+: Wearables, and the flood of data they generate, inch closer to entering the clinic
    Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.
    STAT · 1mo ago↗ source
  • Opinion: Why STAT is sticking with ‘health care’ as two words
    Is it “health care” or “healthcare”? STAT readers had strong feelings.
    STAT · 1mo ago↗ source
  • STAT+: Trump’s health care affordability czar touts Medicaid cuts to hospital leaders
    Hospital execs say they're working to mitigate the impacts of the looming cuts.
    STAT · 1mo ago↗ source
  • A leader of the 2014 U.S. Ebola response compares then to now
    As the world deals with an outbreak of Ebola that has no known cure, Susan Reichle, who last year co-founded Aid Transition Alliance to support former USAID professionals, discusses the…
    STAT · 1mo ago↗ source
  • STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
    GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
    STAT · 1mo ago↗ source
  • Alcohol study discarded by Trump officials is published in scientific journal
    A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.
    STAT · 1mo ago↗ source
  • Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
    Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
    STAT · 1mo ago↗ source
  • STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
    AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
    STAT · 1mo ago↗ source
  • City banks nearly $100M for next-gen RNAi drugs
    Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.
    BioPharma Dive · 1mo ago↗ source
  • Roche stakes $700M on Nurix’s protein-degrading drug
    Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
    BioPharma Dive · 1mo ago↗ source
  • Tango data add to growing momentum for pancreatic cancer drugs
    A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
    BioPharma Dive · 1mo ago↗ source
  • Incyte to buy blood disorder drug in possibly $2B deal
    Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
    BioPharma Dive · 1mo ago↗ source
  • J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
    The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
    BioPharma Dive · 1mo ago↗ source